By staff writers

October 10, 2018 -- Medical isotope developer Vivos late last month completed a common stock equity financing that raised money to eliminate debt and advance product development.

The private placement financing by Vivos, formerly known as Advanced Medical Isotope, included approximately $700,000 of new cash, as well as approximately $900,000 from the conversion of bridge notes, past due compensation, and a long-term loan held by the company's chairman.

Vivos CEO Mike Korenko said the funding is important for the company's efforts to accelerate the development of its yttrium-90 (Y-90) RadioGel brachytherapy device for the human market and for the commercialization of its IsoPet product for the veterinary market.

Copyright © 2018

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking